Takedea will acquire PvP Biologics after the company reports results from its phase 1 proof-of-mechanism study of its treatment for uncontrolled celiac disease.
What you should know:
1. PvP created TAK-062, also known as Kuma062, a drug that could potentially treat celiac disease by degrading undigested gluten.
2. The drug is the subject of a phase 1 study investigating TAK-062's safety and tolerability in healthy patients and patients with celiac disease.
3. To acquire PvP, Takeda paid a negotiated upfront payment and could make additional payments of up to $330 million as the drug passes developmental and regulatory milestones.
4. Takeda and PvP previously entered into a strategic partnership, which granted Takeda acquisition rights in return for developmental funding.